These results suggest that GLP1R agonists in combination with a calcitonin receptor agonist, is able to show even larger decreases in body weight than typical GLP1R agonists, within a shorter time and with a more favourable side effect profile
Giustina A, Mazziotti G, Canalis E
That just means it tells your body to release more of its own growth hormone
Interested in advocating for people living with T1D
In Graves disease, selenium supplementation might facilitate biochemical restoration of euthyroidism and reduce ocular involvement, but these results need to be confirmed
It is structurally distinct from IGF-1 LR3 and acts through what some researchers describe as an MGF-specific receptor pathway, although the precise receptor identification remains debated in the published literature